Tralokinumab is an IL-13 neutralizing monoclonal antibody being investigated for severe asthma. The success of neutralization of IL-5 for the treatment of severe eosinophilic asthma has increased investigation into the therapeutic potential of other type 2 cytokines, including IL-13.
3 recent trials have been conducted to assess the efficacy of tralokinumab, an IL-13 neutralizing mAb, in the treatment of asthma. A study published in the Lancet, studied patients with moderate to severe asthma, they either received placebo or 300mg of tralokinumab every 2 weeks for 12 weeks.
Tralokinumab decreased the fraction of nitric oxide and total blood IgE levels, it did not affect eosinophil counts in the blood and sputum.
In other study, tralokinumab was given every 2 or 4 weeks vs placebo. Tralokinumab did not significantly reduced the overall annualized asthma exacerbation rate.
These findings support the idea that neutralization of IL-13 alone is not sufficient to prevent asthma exacerbation and suggest a requirement for concurrent neutralization of IL-4, by Dupilumab.
There are many new biologic medications that are being studied, to read more about them, see here:
Currently on the market, the biologics that are FDA approved and available are, Xolair, Nucala, Fasenra and Cinqair.
In addition to asthma, other indications are being looked at. For instance, Xolair was initially approved for asthma, but it is now indicated chronic hives.
Other conditions being looked at are COPD, nasal polyps, eosinophilic esophagitis, to name a few.
Overall, the studies for tralokinumab are not promising for severe asthma, more studies will be coming. But if they are not able to get approval, other indications may be on the horizon for it.